Decades of Progress: The Evolution of Treatment of Renal Cell Carcinoma | Dr. Rana Mckay, MD

Rana Mckay, MD
Professor of Medicine and Urology
University of California San Diego

Rana R. McKay, MD, FASCO is an Professor of Medicine and Urology at the University of California San Diego, Associate Director of Clinical Sciences, and Co-Leader of the Genitourinary Oncology Program at the Moores Cancer Center. She is a medical oncologist who specializes in treating people with urogenital cancers. Her research interests include advanced therapeutics, precision medicine, and biomarker development. Her work has appeared in peer-reviewed publications such as The New England Journal of Medicine, Nature, Lancet, Journal of Clinical Oncology, Clinical Cancer Research, Cancer, among others. She is a member of the NCI Renal Task Force, NCI Prostate Cancer Task Force, NRG RCC Cadre Leader, Alliance Advanced Prostate Cancer Cadre Leader, and member of the NCCN Prostate Cancer Guidelines panel. She has been named a Top Doctor in San Diego and recognized by Newsweek as one of America’s Best Prostate Cancer Oncologists. Dr. McKay earned her medical degree at the University of Florida College of Medicine before completing her residency at Johns Hopkins Hospital, Johns Hopkins University. She completed a fellowship in Oncology/Hematology at the Dana-Farber Cancer Institute, Harvard Medical School.

JOIN HERE!

Dr. Mckay’s Objectives:

At the end of the presentation, participants will be able to do the following

• Identify treatment options for patients with localized renal cell carcinoma
• Selection of treatment options for patients with advanced or metastatic renal cell carcinoma
• Integrate the multidisciplinary management of patients with renal cell carcinoma

Faculty Disclosure

Dr. Mckay has indicated that she has the following financial relationships:

Consultant
Ambrx, Arcus, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Eisai,
Johnson & Johnson, Lilly, Merck, Myovant, NeoMorph,Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus.

Planning Committee Disclosure

Dr. Lekakis has indicated that he has no relevant financial relationships with commercial interests.

Target Audience

Faculty, Primary Care Physicians, APRNs, PharmD

Accreditation

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.